COVID-19

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem...

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture

UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech,...

Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding...

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

Predictmedix AI Inc. Selected by Canadian Government for Mexico Trade Mission, Led by Minister Dominic LeBlanc, to Drive Growth and High-Value Partnerships

Participation in Canada's official trade mission provides Predictmedix with exclusive, government-facilitated introductions to Mexican distributors, clients, and industry leaders, accelerating...

error: Content is protected !!